Psoriasis Severity in HIV Associated With Low CD4 T-Cell Count
The characteristics of a general psoriasis populations were compared with that of those patients with psoriasis living with HIV.
The characteristics of a general psoriasis populations were compared with that of those patients with psoriasis living with HIV.
The long-term persistence of various biologic agents in treating psoriasis and psoriatic arthritis are investigated.
In research published online April 15 in Science Immunology, distinct classes of human inflammatory skin disease are defined at the molecular level.
A review regarding the safety, efficacy, and use of apremilast in treating patients with moderate to severe plaque psoriasis of the body and scalp, nail psoriasis, and palmoplantar psoriasis in adults is provided.
Investigators sought to determine whether cTnI and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) were associated with carotid plaque burden and CV events independent of the Framingham Risk Score (FRS).
Predictors for successful dose reduction of adalimumab, etanercept, and ustekinumab for the treatment of psoriasis are assessed.
Cumulative clinical benefits of psoriasis treatment with biologic agents over 1 year are compared.
To evaluate the safety and efficacy of imsidolimab in generalized pustular psoriasis (GPP), the design of a phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial called Gemini-1 (ANB019-301) is proposed.
The efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis is investigated.
The incidence of overall IBD, ulcerative colitis, and Crohn’s disease in patients with and without chronic inflammatory skin disease is compared.